



OVM-200 Phase 1 clinical trial accepted for presentation at ASCO

The American Society of Clinical Oncology has accepted the Phase 1b dose expansion part of the OVM-200 Phase 1 trial for presentation at its annual meeting.

Oxford, UK – 22nd May 2026

Oxford Vacmedix (OVM), the UK biotech company developing novel immunotherapies to treat cancer is very pleased to announce that the Phase 1b dose expansion part of the Phase 1 trial of OVM-200 will be presented at the annual meeting of the American Society of Clinical Oncology in Chicago at the end of May. The poster presentation will be part of the session on Developmental Therapeutics – Immunotherapy. This follows the publication of Phase 1a, which established dosing, in a Lancet group journal earlier this year.

This Phase 1 clinical trial of OVM-200 is a multicentre, open-label, first-in-human evaluation of OVM-200, an immunotherapy developed using Oxford Vacmedix's Recombinant Overlapping Peptide (ROP) therapeutic platform. 36 patients with advanced NSCLC (non-small cell lung cancer) ovarian cancer, or prostate cancer and with no HLA restrictions, were treated in the trial. The results show:

- **Excellent Safety Profile** (primary endpoint): OVM-200 is very well tolerated with no serious adverse drug reactions or no dose-limiting toxicities. The only adverse effects were Grade 1 injection-site reactions.
- **Very strong Immunogenicity** (secondary endpoint): the immune responses for both antibodies and for T cells were very strong even in an advanced Stage IV patient population.
- **Therapeutic Dose established** (secondary endpoint) based on the immune response, the 2mg dose selected in Phase 1a was chosen for expanded immunisations of up to 11 doses of 2mg in Phase 1b.
- **Early observations of clinical efficacy** with stable disease in NSCLC and PSA responses in prostate cancer following progression to other therapies.

Professor Martin Forster, Chief Investigator at University College Hospital, London, said:

“We are very impressed with the results of this Phase 1 trial for OVM-200. In particular, seeing six months stable disease in a Stage IV lung cancer patient is a very promising result, for follow up. We look forward to further development with Phase 2 trials of OVM-200.”

William Finch, Chief Executive Officer of Oxford Vacmedix, said:

“The completion of this clinical trial of OVM-200 marks an important milestone for the company. We are of course very grateful for the participation of the patients and the dedication of the staff in the clinics in this first trial of OVM-200. We are already in discussions about investment to fund Phase 2 development.”

Oxford Vacmedix UK

The Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK

T +44 (0)1865 742087 E enquiries@oxfordvacmedix.com www.oxfordvacmedix.com

END

For more information or to express an interest in investing in Series B please contact:

William Finch, CEO, Oxford Vacmedix

T: +44 (0)1865 784074 | M: +44(0)7769 903711 | E: wfinch@oxfordvacmedix.com

Dr Nam Park, Chief Business Officer, Oxford Vacmedix

T: +44 (0)1865 784074 | M: +44(0)7932 613938 | E: npark@oxfordvacmedix.com

Notes to Editor

About Oxford Vacmedix

Oxford Vacmedix UK Ltd, based at the Oxford Science Park, UK, is a biotech company spun out from the University of Oxford's Department of Oncology. The company is utilising the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Professor Shisong Jiang. ROPs have been validated as a technology to stimulate broad and strong T cell and antibody immunity therefore forming a good platform for therapeutic immunotherapy and diagnostics in cancer and infectious diseases.

OVM is developing two lead immunotherapies, OVM-100 and OVM-200, focusing on unmet clinical need. OVM-100 is an HPV vaccine targeted at cervical cancer, and OVM-200 represents a new type of vaccine utilising survivin to target solid tumours including prostate, ovarian and non-small cell lung cancer (NSCLC). Both immunotherapies will be tested as single agents and in combination with IO agents. OVM has a strong pipeline, with a diagnostic for anti-microbial resistance being tested and one other cancer immunotherapy for pancreatic cancer also in preclinical development.

The company is currently seeking Series B funding to advance OVM-200 to Phase 2 and OVM-100 into Phase 1 trials, as monotherapy and in combination.

For more information: <http://www.oxfordvacmedix.com>

About ASCO

Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.

ASCO promotes and provides for

- Lifelong learning for oncology professionals,
- Cancer research,
- An improved environment for oncology practice,
- Access to quality cancer care,
- A global network of oncology expertise, and
- Educated and informed patients with cancer

ASCO is supported by its affiliate organization, Conquer Cancer, the ASCO Foundation which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer.

For more information: <https://www.asco.org>